Company Overview of Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. It is developing two extracts, including Phytofare Catechin Complex, which is derived from green tea harvested in the Senteeko Tea Estate in Mpumalanga, South Africa; and Phytofare Limonoid Glycoside Complex extracted from lemons that are sourced from plantations in South Africa. The company also produces and sells timber and agricultural products from its farm and tea estate holdings in South Africa. In addition, it intends to use its plantation leases to focus on the farming of whole fruits, vegetables, and live plant material. The company is based in...
2226 Eastlake Avenue East
Seattle, WA 98102
Key Executives for Plandaí Biotechnology, Inc.
Total Annual Compensation: $117.5K
Vice President of Sales and Director
Total Annual Compensation: $95.0K
Vice President of Marketing and Director
Total Annual Compensation: $9.0K
Compensation as of Fiscal Year 2014.
Plandaí Biotechnology, Inc. Key Developments
Plandaí Biotechnology, Inc. announced delayed annual 10-K filing
Sep 29 14
On 09/29/2014, Plandaí Biotechnology, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Plandai Biotechnology Plans to Develop and Test an All-Natural Phytofare Extract for Erectile Dysfunction
Sep 22 14
Plandai Biotechnology announced its preliminary plans to develop and test an all-natural Phytofare(TM) extract for erectile dysfunction (ED). With an ED market that brings in billions annually, it's not hard to figure out why Plandai would use its unique and proprietary extraction process to try to develop and test another possible extract -- this time providing an all-natural alternative to existing ED drugs like Viagra(r) and Cialis(r). The company's expectation, assuming the ED product would be effective and safe after conducting research, development and testing, would be to market and sell the extract as an active ingredient to pharmaceutical and nutraceutical manufacturers. Plandai recently announced that it has begun cultivating and cloning epimedium, a plant with the known ability to treat erectile dysfunction, and expects to commence testing on the possible ED product mid-2015. This month Plandai received preliminary results from a human clinical trial conducted in South Africa by North West University. The results of those tests indicate that using Plandai's technology resulted in a green tea extract with 10 times more potency than the commercially available extract it was compared to in the study. Plandai expects to duplicate that success with a special strain of epimedium that contains high levels of icariin, the primary active compound which studies have shown may treat ED. Epimedium, also known as "horny goat weed" contains icariin, which is a Phosphodiesterase type 5 (PDE5) inhibitor like sildenafil, the active ingredient in the erectile dysfunction drug Viagra. In fact, icariin was cited by the US Patent Office as a known PDE5 inhibitor when it denied portions of Pfizer's Viagra patent. While icariin has less potency than sildenafil, Plandai believes its extraction process will enhance epimedium's absorption and retention in the bloodstream, resulting in an-natural extract that the company anticipates will function much like Viagra.
Plandaí Biotechnology Releases Preliminary Results
Sep 10 14
Plandaí Biotechnology announced that it has recently released the preliminary results from its human clinical trial where the company's green tea extract, Phytofare Catechin Complex, was clinically tested and compared to a commercially available green tea extract. In the clinical trial, the company’s Phytofare extract product showed greater bioavailability to participants than did the commercial extract by a factor of 10. These results echo the USDA's findings that were published in 2012. The USDA concluded that the company’s proprietary extraction process for treating vegetable matter provides more bioavailability and more benefit to consumers. So, now in 2014, we're presented with even more evidence that the extraction process delivers greater bioavailability with this clinical trial conducted in South Africa by North West University. The company’s extract has now shown in the preliminary results of a clinical trial that it can deliver more of what many believe makes green tea healthy. For the health benefits of the green tea plant to be realized and to be beneficial, however, the catechins have to be absorbed into the body and then remain in the bloodstream long enough to be effective. According to Professor Anne Grobler of North West University, Plandaí's product showed that by using the company's extraction process, which unzips and reconfigures the plant's molecules to be more accepted by the human body, with Phytofare(TM) all 8 of the plant's catechins were present in the bloodstream versus only 2 catechins detected in the bloodstream when the commercial extract was tested. Additionally, the trial's results found that when using the company's technology, absorption of those catechins was 5 times greater, and the life span of the catechin's molecules in the bloodstream was doubled in Phytofare when compared to that of the commercial green tea extract. The significance of these results to the company is that an extract that allows the body to experience more of the health benefits of green tea is expected to have a significant market advantage over traditional green tea products where most of the catechins are lost through metabolization before they ever enter the bloodstream. Simply put, the company’s product delivers significantly more of the nutrients and then those nutrients remain in the bloodstream twice as long.
Similar Private Companies By Industry
Recent Private Companies Transactions